119 related articles for article (PubMed ID: 9061062)
1. New SCM (structuredness of the cytoplasmatic matrix)-based approach in breast cancer detection.
Birindelli S; Colnaghi MI; Pilotti S
Tumori; 1996; 82(6):550-3. PubMed ID: 9061062
[TBL] [Abstract][Full Text] [Related]
2. Tumour specificity of the SCM test for cancer diagnosis.
Chaitchik S; Asher O; Deutsch M; Weinreb A
Eur J Cancer Clin Oncol; 1985 Oct; 21(10):1165-70. PubMed ID: 2416568
[TBL] [Abstract][Full Text] [Related]
3. An approach for high sensitivity detection of prostate cancer by analysis of changes in structuredness of the cytoplasmic matrix of lymphocytes specifically induced by PSA-ACT.
Klein O; Lin S; Embon O; Sazbon A; Zidan J; Kook AI
J Urol; 1999 Jun; 161(6):1994-6. PubMed ID: 10332488
[TBL] [Abstract][Full Text] [Related]
4. Adaptation of the cellscan technique for the SCM test in breast cancer.
Rahmani H; Deutsch M; Ron I; Gerbat S; Tirosh R; Weinreb A; Chaitchik S; Lalchuk S
Eur J Cancer; 1996 Sep; 32A(10):1758-65. PubMed ID: 8983287
[TBL] [Abstract][Full Text] [Related]
5. Detection of melanoma by monitoring the intracellular fluorescein fluorescence polarization changes in lymphocytes.
Merimsky O; Kaplan B; Deutsch M; Tirosh R; Weinreb A; Chaitchik S
Cancer Detect Prev; 1997; 21(2):167-77. PubMed ID: 9101078
[TBL] [Abstract][Full Text] [Related]
6. [Lymphocyte subsets and response of breast cancer and benign mammary disease to PHA].
Nakao S; Hayashida K; Hasegawa H; Ishii T; Eida K; Noguchi K
Gan No Rinsho; 1987 Oct; 33(12):1453-8. PubMed ID: 3500331
[TBL] [Abstract][Full Text] [Related]
7. Serum CYFRA 21-1 is one of the most reliable tumor markers for breast carcinoma.
Nakata B; Ogawa Y; Ishikawa T; Ikeda K; Kato Y; Nishino H; Hirakawa K
Cancer; 2000 Sep; 89(6):1285-90. PubMed ID: 11002224
[TBL] [Abstract][Full Text] [Related]
8. Biophysical differentiation between lymphocytes from healthy donors, patients with malignant diseases and other disorders.
Cercek L; Cercek B; Franklin CI
Br J Cancer; 1974 May; 29(5):345-52. PubMed ID: 4136566
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic ability of different human milk fat globule antigens in breast cancer.
Ceriani RL; Blank EW; Rosenbaum EH; Ben Zeev D; Lowitz RS; Johansen L; Trujillo T
Breast Cancer Res Treat; 1990 May; 15(3):161-74. PubMed ID: 2372570
[TBL] [Abstract][Full Text] [Related]
10. [Circulating proteinic biomarkers and breast cancer].
Mathelin C; Koehl C; Rio MC
Gynecol Obstet Fertil; 2006; 34(7-8):638-46. PubMed ID: 16876456
[TBL] [Abstract][Full Text] [Related]
11. CA-15.3, TPA and MCA as markers for breast cancer.
Barak M; Steiner M; Finkel B; Abrahamson J; Antal S; Gruener N
Eur J Cancer; 1990; 26(5):577-80. PubMed ID: 2144745
[TBL] [Abstract][Full Text] [Related]
12. Mucin-like cancer-associated antigen (MCA) compared with CA 15-3 in advanced breast cancer.
Steger GG; Mader R; Derfler K; Moser K; Dittrich C
Klin Wochenschr; 1989 Aug; 67(16):813-7. PubMed ID: 2796251
[TBL] [Abstract][Full Text] [Related]
13. Preparation of a diagnostic antigen of human melanoma based on lymphocyte activation as measured by intracellular fluorescein fluorescence polarization.
Avtalion N; Avtalion R; Tirosh R; Sheinberg A; Weinreb A; Avinoach I; Deutsch M
Cancer Detect Prev; 1999; 23(1):64-71. PubMed ID: 9892992
[TBL] [Abstract][Full Text] [Related]
14. Pre-existing T-cell immunity against mucin-1 in breast cancer patients and healthy volunteers.
Gückel B; Rentzsch C; Nastke MD; Marmé A; Gruber I; Stevanović S; Kayser S; Wallwiener D
J Cancer Res Clin Oncol; 2006 Apr; 132(4):265-74. PubMed ID: 16374613
[TBL] [Abstract][Full Text] [Related]
15. Deficient concanavalin-A-induced suppressor cell activity in women with untreated breast cancer.
Gupta S; Cunningham-Rundles S
J Clin Lab Immunol; 1982 Dec; 9(3):159-61. PubMed ID: 6220154
[TBL] [Abstract][Full Text] [Related]
16. Breast epithelial antigens in the circulation of breast cancer patients.
Ceriani RL; Rosenbaum EH
Immunol Ser; 1990; 53():223-41. PubMed ID: 2100557
[No Abstract] [Full Text] [Related]
17. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
18. Nipple discharge of CA15-3, CA125, CEA and TSGF as a new biomarker panel for breast cancer.
Wang G; Qin Y; Zhang J; Zhao J; Liang Y; Zhang Z; Qin M; Sun Y
Int J Mol Sci; 2014 May; 15(6):9546-65. PubMed ID: 24879526
[TBL] [Abstract][Full Text] [Related]
19. Fluorescence polarisation changes in lymphocyte cytoplasm as a diagnostic test for breast carcinoma.
Ron IG; Deutsch M; Tirosh R; Weinreb A; Eisenthal A; Chaitchik S
Eur J Cancer; 1995 Jun; 31A(6):917-20. PubMed ID: 7646921
[TBL] [Abstract][Full Text] [Related]
20. Serum level of cryptic tumor antigens in breast cancer patients as determined by two monoclonal antibodies (M85/F36) and its comparison with CA 15-3.
Chu TM; Constantine R; Nemoto T
J Clin Lab Anal; 1989; 3(5):267-72. PubMed ID: 2681619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
